Relmada names Jørn Skibsted Jakobsen chief development officer ahead of NDV-01 Phase 3Nov 16PeopleRelmada Therapeutics, Inc.sustained-release gemcitabine-docetaxel
Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Relmada targets year-end IND filings for NDV-01 and sepranolone, reports $217.7M cashAug 6Quarterly updateRelmada Therapeutics, Inc.sustained-release gemcitabine-docetaxel
Relmada names Bipin Dalmia as Chief Business OfficerJul 28PeopleRelmada Therapeutics, Inc.sustained-release gemcitabine-docetaxel